Advertisement
BSX vs MDT
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- Boston Scientific (BSX) is trading at a sharply lower valuation after a steep decline, while Medtronic (MDT) has shown signs of a multi-year turnaround with its strongest revenue growth in a decade.
- BSX's recent pressure stems largely from a WATCHMAN slowdown, softer electrophysiology results, and a reduced 2026 outlook, offset by strength in Interventional Cardiology and Neuromodulation.
- MDT is expanding margins, accelerating its higher-growth platforms such as Affera and Symplicity, and carries a dividend yield above 3% with 49 consecutive years of increases.
- Both stocks remain below analyst fair-value estimates, but their risk profiles differ: BSX faces near-term execution and integration risk, while MDT faces turnaround-sustainability questions.
- BSX trades at roughly 14x forward earnings versus MDT's roughly 15x, a relatively narrow gap despite their very different momentum profiles.
- For deeper, real-time context, explore BSX Major News and BSX Today's Price Move, along with MDT Major News and MDT Today's Price Move.
- To see how automated strategies are positioning across the market, browse the Trending AI Robots.
Introduction
Boston Scientific and Medtronic are two of the largest names in medical technology, yet they sit at very different points in their business cycles. This stock comparison is relevant for investors and traders weighing a growth-oriented, higher-momentum device maker against a diversified, dividend-paying industry giant that has underperformed for years. Because the two companies compete in overlapping cardiovascular and electrophysiology markets while diverging sharply in recent relative performance, they offer a useful lens on how market positioning, growth catalysts, and valuation interact in the current environment.
BSX Overview and Recent Performance
BSX is a global medical device company spanning cardiovascular, endoscopy, urology, and neuromodulation. Recent market activity has been marked by a significant re-rating lower, with the stock well below its levels of a year ago. The principal drivers have been a sharp and unexpected slowdown in its WATCHMAN left atrial appendage closure franchise and competitive share pressure in U.S. electrophysiology, which together prompted management to reduce its 2026 growth outlook. Notably, roughly 75% of revenue still sits outside those two areas, with Interventional Cardiology and Neuromodulation posting double-digit growth in recent quarters. Investors have also weighed the pending Penumbra acquisition, a restructuring program targeting roughly $500 million in annual savings, and a product recall in its angiography catheter line.
MDT Overview and Recent Performance
MDT is the world's largest pure-play medical device company, operating across cardiovascular, neuroscience, medical surgical, and diabetes segments. After years of relative underperformance, recent quarters have pointed toward a turnaround: fiscal 2026 revenue rose 8.4% to roughly $36.4 billion, its fastest top-line growth in a decade, and the most recent quarter delivered strong segment-level momentum led by an 80% gain in Ablation Solutions and double-digit Cardiovascular growth. Recent regulatory wins include permanent reimbursement codes for its Altaviva neuromodulation implant and Symplicity Spyral renal denervation system, plus new clearances in surgical robotics. MDT also offers an attractive income profile, with a dividend yield above 3% and 49 straight years of increases, though margin pressure from tariffs and the MiniMed diabetes spin-off remain watchpoints.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies drawn from a much larger universe of hundreds of AI Trading Bots that trade thousands of different tickers. Because each bot is built with its own trading style, strategy, timeframe, performance history, and set of tickers, only those best suited to current market conditions earn a place in this section. The platform highlights metrics such as win rates, drawdowns, and trade frequency, helping traders compare approaches at a glance. For investors tracking relative performance and market positioning in names like BSX and MDT, reviewing the Trending AI Robots can offer a complementary, data-driven perspective on how automated systems are interpreting the same conditions.
Head-to-Head Comparison
The two companies contrast most sharply on growth trajectory and market positioning. BSX has historically been a faster grower with a more concentrated catalyst set, but its recent guidance cut highlights how quickly momentum can reverse when a single high-profile franchise underperforms. MDT, by contrast, is a far more diversified operator whose turnaround depends on sustaining broad-based growth across many segments rather than any single product.
On valuation, the two are closer than their narratives suggest. BSX trades near 14x forward earnings and MDT near 15x, so the market is not assigning a large premium to BSX's growth profile today. Risk factors also differ: BSX carries acquisition-integration and execution risk tied to Penumbra and its restructuring, while MDT faces tariff-related margin pressure, competition in cardiovascular and robotics, and uncertainty around the MiniMed separation. Sector exposure is overlapping in cardiac rhythm and electrophysiology, where the two compete directly, but MDT's neuroscience and diabetes breadth provides diversification that BSX's portfolio lacks. Market sentiment has favored MDT's stabilizing narrative in recent weeks, even as BSX remains lower on the year.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst momentum, and relative positioning, Tickeron's AI would likely lean toward MDT in the current environment. Medtronic is showing a more consistent pattern of improving fundamentals, accelerating high-growth platforms, and strengthening analyst sentiment, supported by a stable dividend and a lower-beta profile. Boston Scientific still offers a compelling growth story in segments such as Interventional Cardiology, but its near-term outlook remains clouded by the WATCHMAN slowdown and integration risk, making its trend less clearly established. This assessment reflects probabilistic positioning rather than a definitive forecast, and either stock could shift as fresh earnings and catalyst data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a StrongBuy and MDT is a Hold.
Momentum Indicator for BSX turns positive, indicating new upward trend
BSX saw its Momentum Indicator move above the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 56 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 15 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on November 09, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 25 of 46 cases over the following month. The odds of a continued upward trend are 54%.
BSX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 201 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MDT in -3.01% downward trend, declining for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDT declined for three days, in 165 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 11 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 67 cases where MDT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 43%.
MDT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 47 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 23 of 42 cases over the following month. The odds of a continued upward trend are 55%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 35%.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 171 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 237 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.592) is normal, around the industry mean (4.142). P/E Ratio (24.890) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.253). Dividend Yield (0.028) settles around the average of (0.011) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BSX | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 97 | 100 | |
SMR RATING 1..100 | 55 | 68 | |
PRICE GROWTH RATING 1..100 | 62 | 15 | |
P/E GROWTH RATING 1..100 | 95 | 48 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (65) in the Medical Specialties industry is in the same range as BSX (66). This means that MDT’s stock grew similarly to BSX’s over the last 12 months.
BSX's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as MDT (100). This means that BSX’s stock grew similarly to MDT’s over the last 12 months.
BSX's SMR Rating (55) in the Medical Specialties industry is in the same range as MDT (68). This means that BSX’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (15) in the Medical Specialties industry is somewhat better than the same rating for BSX (62). This means that MDT’s stock grew somewhat faster than BSX’s over the last 12 months.
MDT's P/E Growth Rating (48) in the Medical Specialties industry is somewhat better than the same rating for BSX (95). This means that MDT’s stock grew somewhat faster than BSX’s over the last 12 months.
| BSX | MDT | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 60% | 2 days ago 42% |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 43% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 55% |
| MACD ODDS (%) | 2 days ago 54% | 2 days ago 55% |
| TrendWeek ODDS (%) | 2 days ago 55% | 2 days ago 53% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 60% | 15 days ago 54% |
| Declines ODDS (%) | 7 days ago 54% | 7 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 40% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 37% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 5 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s).
- BSX’s TA Score: 5 bullish, 4 bearish.
- MDT’s TA Score: 6 bullish, 4 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а -1.51% price change this week, while MDT (@Medical/Nursing Services) price change was -3.19% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +5.70%. For the same industry, the average monthly price growth was -2.49%, and the average quarterly price growth was -1.73%.
Reported Earning Dates
BSX is expected to report earnings on Feb 03, 2027.
MDT is expected to report earnings on Nov 24, 2026.
Industries' Descriptions
@Medical/Nursing Services (+5.70% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +0.96% | ||
| ISRG - BSX | 71% Closely correlated | -0.11% | ||
| MMSI - BSX | 56% Loosely correlated | +0.30% | ||
| ALC - BSX | 49% Loosely correlated | -2.16% | ||
| MDT - BSX | 48% Loosely correlated | +0.02% | ||
| NTRA - BSX | 45% Loosely correlated | +2.51% | ||
More | ||||
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.